J. S. Smolen and D. Aletaha, Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges, Nat Rev Rheumatol, vol.11, issue.5, pp.276-89, 2015.

J. L. Nam, S. Ramiro, C. Gaujoux-viala, K. Takase, M. Leon-garcia et al., Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis, Ann Rheum Dis, vol.73, issue.3, pp.516-544, 2014.

M. E. Orme, K. S. Macgilchrist, S. Mitchell, D. Spurden, and A. Bird, Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70, Biologics, vol.6, pp.429-64, 2012.

S. Ramiro, C. Gaujoux-viala, J. L. Nam, J. S. Smolen, M. Buch et al., Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, Ann Rheum Dis, vol.73, issue.3, pp.529-564, 2014.

J. A. Singh, R. Christensen, G. A. Wells, M. E. Suarez-almazor, R. Buchbinder et al., A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview, CMAJ, vol.181, issue.11, pp.787-96, 2009.

J. A. Singh, G. A. Wells, R. Christensen, T. Ghogomu, E. Maxwell et al., Adverse effects of biologics: a network meta-analysis and Cochrane overview, Cochrane Database Syst Rev, vol.2, p.8794, 2011.

C. Gaujoux-viala, L. Gossec, A. Cantagrel, M. Dougados, B. Fautrel et al., Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis, Joint Bone Spine, vol.81, issue.4, pp.287-97, 2014.

J. A. Singh, D. E. Furst, A. Bharat, J. R. Curtis, A. F. Kavanaugh et al., American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis, Arthritis Care Res (Hoboken), vol.64, issue.5, pp.625-664, 2008.

J. S. Smolen, F. C. Breedveld, G. R. Burmester, V. Bykerk, M. Dougados et al., Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force, Ann Rheum Dis, vol.75, issue.1, pp.3-15, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01890959

G. Lenz, G. Wright, S. S. Dave, X. W. Powell, J. Zhao et al., Stromal gene signatures in large-B-cell lymphomas, N Engl J Med, vol.359, issue.22, pp.2313-2336, 2008.

M. Suthanthiran, J. E. Schwartz, R. Ding, M. Abecassis, D. Dadhania et al., Urinary-cell mRNA profile and acute cellular rejection in kidney allografts, N Engl J Med, vol.369, issue.1, pp.20-31, 2013.

C. Markopoulos, C. Van-de-velde, D. Zarca, V. Ozmen, and R. Masetti, Clinical evidence supporting genomic tests in early breast cancer: do all genomic tests provide the same information?, Eur J Surg Oncol, vol.43, pp.909-929, 2017.

A. N. Burska, K. Roget, M. Blits, S. Gomez, L. Van-de-loo et al., Gene expression analysis in RA: towards personalized medicine, Pharmacogenomics J, vol.14, issue.2, pp.93-106, 2014.

T. D. De-jong, S. Vosslamber, and C. L. Verweij, Moving towards personalized medicine in rheumatoid arthritis, Arthritis Res Ther, vol.16, issue.3, p.110, 2014.

T. Haupl, B. Stuhlmuller, A. Grutzkau, A. Radbruch, and G. R. Burmester, Does gene expression analysis inform us in rheumatoid arthritis?, Ann Rheum Dis, vol.69, issue.1, pp.37-42, 2010.

L. Folkersen, B. Brynedal, L. M. Diaz-gallo, D. Ramskold, K. Shchetynsky et al., Integration of known DNA, RNA and protein biomarkers provides prediction of anti-TNF response in rheumatoid arthritis: results from the COMBINE study, Mol Med, vol.22, pp.322-330, 2016.

C. Bansard, T. Lequerre, C. Derambure, O. Vittecoq, M. Hiron et al., Gene profiling predicts rheumatoid arthritis responsiveness to IL-1Ra (anakinra), Rheumatology (Oxford), vol.50, issue.2, pp.283-92, 2010.
URL : https://hal.archives-ouvertes.fr/hal-02329564

T. Lequerre, A. C. Gauthier-jauneau, C. Bansard, C. Derambure, M. Hiron et al., Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis, Arthritis Res Ther, vol.8, issue.4, p.105, 2006.
URL : https://hal.archives-ouvertes.fr/inserm-00089669

S. B. Krintel, C. Dehlendorff, M. L. Hetland, K. Horslev-petersen, K. K. Andersen et al., Prediction of treatment response to adalimumab: a doubleblind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis, Pharmacogenomics J, vol.16, issue.2, pp.141-147, 2015.

Y. Sanayama, K. Ikeda, Y. Saito, S. Kagami, M. Yamagata et al., Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray, Arthritis Rheum, vol.66, issue.6, pp.1421-1452, 2014.

J. Sellam, S. Marion-thore, F. Dumont, S. Jacques, H. J. Garchon et al., Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial, Arthritis Rheum, vol.66, issue.8, pp.2015-2040, 2014.

M. A. D'agostino, M. Boers, R. J. Wakefield, B. Hammer, H. Vittecoq et al., Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study, RMD Open, vol.2, issue.1, p.237, 2016.

M. A. D'agostino, R. J. Wakefield, H. Berner-hammer, O. Vittecoq, G. Filippou et al., Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study, Ann Rheum Dis, vol.75, issue.10, pp.1763-1772, 2016.

F. C. Arnett, S. M. Edworthy, D. A. Bloch, D. J. Mcshane, J. F. Fries et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum, vol.31, issue.3, pp.315-339, 1988.

D. M. Van-der-heijde, M. A. Van't-hof, P. L. Van-riel, L. A. Theunisse, E. W. Lubberts et al., Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score, Ann Rheum Dis, vol.49, issue.11, pp.916-936, 1990.

J. Vandesompele, D. Preter, K. Pattyn, F. Poppe, B. Van-roy et al., Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes, Genome Biol, vol.3, issue.7, p.34, 2002.

J. E. Gottenberg, D. Neto, J. Gomez-reino, F. Iannone, E. Lie et al., Positivity for rheumatoid factor and anti-cyclic citrullinated peptide is associated with a better drug retention of abatacept: data from a pan European analysis of RA registries, Ann Rheum Dis, vol.73, issue.2, pp.502-505, 2014.

J. E. Gottenberg, P. Ravaud, A. Cantagrel, B. Combe, R. M. Flipo et al., Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry, Ann Rheum Dis, vol.71, issue.11, pp.1815-1824, 2012.

H. G. Nusslein, R. Alten, M. Galeazzi, H. M. Lorenz, M. T. Nurmohamed et al., Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study, BMC Musculoskelet Disord, vol.16, p.176, 2015.

M. Scarsi, T. Ziglioli, and P. Airo, Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis, J Rheumatol, vol.38, issue.10, pp.2105-2116, 2011.

E. J. Toonen, C. Gilissen, B. Franke, W. Kievit, A. M. Eijsbouts et al., Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis, PLoS One, vol.7, issue.3, p.33199, 2012.

K. A. Serikawa, S. Jacobsen, D. Lundsgaard, B. A. Fox, L. Hummelshoj et al., Detection of gene expression signatures related to underlying disease and treatment in rheumatoid arthritis patients, Mod Rheumatol, vol.23, issue.4, pp.729-769, 2012.

S. Nakamura, K. Suzuki, H. Iijima, Y. Hata, C. R. Lim et al., Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study, Arthritis Res Ther, vol.18, p.159, 2016.

A. W. Nicholson, Ribonuclease III, mechanisms of double-stranded RNA cleavage, Wiley Interdiscip Rev RNA, vol.5, issue.1, pp.31-48, 2013.

I. Scott, B. R. Webster, J. H. Li, and M. N. Sack, Identification of a molecular component of the mitochondrial acetyltransferase programme: a novel role for GCN5L1, Biochem J, vol.443, issue.3, pp.655-61, 2012.

D. Fornuskova, L. Stiburek, L. Wenchich, K. Vinsova, H. Hansikova et al., Novel insights into the assembly and function of human nuclear-encoded cytochrome c oxidase subunits 4, 5a, 6a, 7a and 7b, Biochem J, vol.428, issue.3, pp.363-74, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00486858

H. Y. Chang, T. C. Huang, N. N. Chen, H. C. Huang, and H. F. Juan, Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells, Cell Death Dis, vol.5, p.1540, 2014.

O. Leavy, T cells: Mitochondria and T cell activation, Nat Rev Immunol, vol.13, issue.4, p.224, 2013.

L. A. Sena, S. Li, A. Jairaman, M. Prakriya, T. Ezponda et al., Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling, Immunity, vol.38, issue.2, pp.225-261, 2013.

S. Devadas, L. Zaritskaya, S. G. Rhee, L. Oberley, and M. S. Williams, Discrete generation of superoxide and hydrogen peroxide by T cell receptor stimulation: selective regulation of mitogen-activated protein kinase activation and fas ligand expression, J Exp Med, vol.195, issue.1, pp.59-70, 2002.

C. Ledderose, Y. Bao, M. Lidicky, J. Zipperle, L. Li et al., Mitochondria are gate-keepers of T cell function by producing the ATP that drives purinergic signaling, J Biol Chem, vol.289, issue.37, pp.25936-25981, 2014.

J. F. Turrens, Mitochondrial formation of reactive oxygen species, J Physiol, vol.552, issue.2, pp.335-379, 2003.

P. H. Remans, C. A. Wijbrandts, M. E. Sanders, R. E. Toes, F. C. Breedveld et al., CTLA-4IG suppresses reactive oxygen species by preventing synovial adherent cell-induced inactivation of Rap1, a Ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cells, Arthritis Rheum, vol.54, issue.10, pp.3135-3178, 2006.

P. H. Remans, S. I. Gringhuis, J. M. Van-laar, M. E. Sanders, E. A. Der-papendrecht-van-der-voort et al., Rap1 signaling is required for suppression of Ras-generated reactive oxygen species and protection against oxidative stress in T lymphocytes, J Immunol, vol.173, issue.2, pp.920-951, 2004.

M. Aichler, M. Elsner, N. Ludyga, A. Feuchtinger, V. Zangen et al., Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria, J Pathol, vol.230, issue.4, pp.410-419, 2013.

H. Zhu, L. Chen, W. Zhou, Z. Huang, J. Hu et al., Over-expression of the ATP5J gene correlates with cell migration and 5-fluorouracil sensitivity in colorectal cancer, PLoS One, vol.8, issue.10, p.76846, 2013.

T. Ni-chonghaile, K. A. Sarosiek, T. T. Vo, J. A. Ryan, A. Tammareddi et al., Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy, Science, vol.334, issue.6059, pp.1129-1162, 2011.